Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
Merck Sharp & Dohme LLC
Lisa Licitra; Makoto Tahara; Kevin Harrington; Mivael Olivera Hurtado de Mendoza; Ye Guo; Sercan Aksoy; Meiyu Fang; Tibor Csőszi; Mikhail Klochikhin; Thiago Bueno de Oliveira; Shunji Takahashi; Muh-Hwa Yang; Paul L Swiecicki; Caroline Even; Jérome Fayette; Corina Dutcus; Chinyere E Okpara; Juan Shen; Kimberly Benjamin; Burak Gumuscu; Robert I Haddad; LEAP-010 investigators